Business Segments · R&D
Established Pharmaceuticals — R&D
Abbott Established Pharmaceuticals — R&D decreased by 16.3% to $41.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.4%, from $42.00M to $41.00M. Over 3 years (FY 2022 to FY 2025), Established Pharmaceuticals — R&D shows relatively stable performance with a -1.8% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toR&D
How to read this metric
Higher spending indicates a focus on innovation and future growth, while lower spending may signal a focus on short-term margin preservation.
Detailed definition
This metric tracks the investment in scientific research, clinical trials, and product development specifically for the...
Peer comparison
Standard R&D expense reporting for pharmaceutical business units across the industry.
Metric ID:
abt_segment_established_pharmaceuticals_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $46.50M | $46.50M | $46.50M | $46.50M | $43.25M | $43.25M | $43.25M | $43.25M | $41.00M | $44.00M | $46.00M | $45.00M | $42.00M | $43.00M | $42.00M | $49.00M | $41.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -7.0% | +0.0% | +0.0% | +0.0% | -5.2% | +7.3% | +4.5% | -2.2% | -6.7% | +2.4% | -2.3% | +16.7% | -16.3% |
| YoY Change | — | — | — | — | -7.0% | -7.0% | -7.0% | -7.0% | -5.2% | +1.7% | +6.4% | +4.0% | +2.4% | -2.3% | -8.7% | +8.9% | -2.4% |
Range$41.00M – $49.00M
CAGR-3.1%
Avg YoY Growth-1.8%
Median YoY Growth-2.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Abbott's established pharmaceuticals — r&d?
- Abbott (ABT) reported established pharmaceuticals — r&d of $41.00M in Q1 2026.
- How has Abbott's established pharmaceuticals — r&d changed year-over-year?
- Abbott's established pharmaceuticals — r&d decreased by 2.4% year-over-year, from $42.00M to $41.00M.
- What is the long-term trend for Abbott's established pharmaceuticals — r&d?
- Over 3 years (2022 to 2025), Abbott's established pharmaceuticals — r&d has grown at a -1.8% compound annual growth rate (CAGR), from $186.00M to $176.00M.
- What does established pharmaceuticals — r&d mean?
- The amount spent on research and development activities for this specific segment.